| DB ID | MyCo_7133 |
| Title | Comparative performance evaluation of Wako β-glucan test and Fungitell assay for the diagnosis of invasive fungal diseases |
| Year | 2020 |
| PMID | 32726358 |
| Fungal Diseases involved | Pneumocystis carinii pneumonia |
| Associated Medical Condition | None |
| Genus | Pneumocystis |
| Species | carinii |
| Organism | Pneumocystis carinii |
| Ethical Statement | This study was conducted at the Fondazione Policlinico Universitario A. Gemelli (FPG) IRCCS of Rome, Italy, and was approved by the Ethics Committee of the FPG (application number 38367/19) and a waiver of informed consent was granted. Sample processing and data analysis were performed anonymously. |
| Site of Infection | None |
| Opportunistic invasive | Opportunistic |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | BDG |
| Biomarker Full Name | 1-3-beta-D-Glucan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Italy |
| Cohort | Here conducted a retrospective performance assessment study on archived patients’ serum samples, which had been collected as part of routine clinical care at the FPG IRCCS, a large tertiary care hospital in Rome, Italy. The Fungitell assay (FA) and Wako β-glucan test (GT) performances were compared in sera of patients with invasive aspergillosis (IA) (n = 40), invasive candidiasis (IC) (n = 78), and (Pneumocystis jirovecii pneumonia)PJP (n = 17) with respect to sera of control patients (n = 187). |
| Cohort No. | 322 |
| Age Group | None |
| P Value | p<0.05 |
| Sensitivity | 0.941 |
| Specificity | 0.973 |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Invasive aspergillosis (IA), invasive candidiasis (IC), and Pneumocystis pneumonia (PJP, previously known as PCP) represent the most prevalent invasive fungal diseases (IFDs) worldwide. These diseases mainly affect immunocompromised (or immunosuppressed) hosts, causing estimated over 1.6 million deaths annually. Causative agents of IC include different Candida species, whereas the main cause of IA remains Aspergillus fumigatus and PJP is uniquely caused by Pneumocystis jirovecii, formerly Pneumocystis carinii. As IFD symptoms can be subtle and/or nonspecific, it is difficult to identify and treat the cause of disease, especially in patients with hematological malignancies. Furthermore, microbiological confirmation of IFD with conventional, culture-dependent methods may yield false-negative results, hence, molecular, culture-independent methods to enhance the diagnostic sensitivity need to be developed. Thus, pending the microbiological diagnosis, an empirical treatment targeting infectious and non-infectious causes may be necessary. |
| Technique | Analytic |
| Analysis Method | Wako β-glucan test |
| ELISA kits | None |
| Assay Data | FDA- Fungitell® assay, Wako β-glucan test |
| Validation Techniques used | Wako β-glucan test |
| Up Regulation Down Regulation | Increase |
| Sequence Data | None |
| External Link | None |
